A recent report suggested that intraperitoneal administration of anlotinib attenuates bleomycin-induced lung fibrosis in mice by suppressing the TGF-β signaling pathway (Ruan et al., 2020). This evidence concerns the gene TGFB1 and pulmonary fibrosis.